The FDA is alerting healthcare professionals and patients about decreased survival associated with the use of pembrolizumab or atezolizumab as monotherapy therapy in clinical trials.
Posts in Oncology
ISMP leverages multidisciplinary expertise across hundreds of similar healthcare facilities to provide customized guidance on effective use of medication safety data.
In July, ISMP Canada published selected findings from the 2012 ISMP International Medication Safety Self Assessment for Oncology . 1 The assessment, which was funded by the International Society of Oncology Pharmacy Practitioners (ISOPP), was developed by ISMP and ISMP Canada with help from an...
This assessment offers hospitals, long-term care facilities, and outpatient facilities a unique opportunity to assess the safety of systems and practices associated with up to 11 categories of high-alert medications.
The ISMP Medication Safety Self Assessment® for Oncology is designed to heighten awareness of distinguishing systems and practices related to the safe use of chemotherapy, biotherapy, and treatment-related drugs.
Last month the US Food and Drug Administration (FDA) granted accelerated approval to PRAXBIND (idarucizumab) for use in patients who take PRADAXA (dabigatran) and suffer a life-threatening bleeding event. Hospital pharmacies may stock Praxbind if dabigatran patients are treated in the hospital or...
Problem: ISMP has received three reports of accidental overdoses with fluorouracil in 2015—two within the past 6 weeks. Approved more than 50 years ago, fluorouracil was one of the first intravenous cancer drugs and is still a mainstay in combination curative or palliative therapy regimens treating...
Harness ISMP’s unparalleled experience and expertise to uncover root causes and hidden system failures and assist your organization in developing a comprehensive plan of action.
From one day high-alert safety check-ups to comprehensive enterprise risk assessments, ISMP helps uncover systemic areas that are vulnerable to medication error risk in your organization.